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Skin Autofluorescence
A tool to identify type 2 diabetic patients at risk for developing
microvascular complications
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OBJECTIVE— Skin autofluorescence is a noninvasive measure of the level of tissue accu-
mulation of advanced glycation end products, representing cumulative glycemic and oxidative
stress. Recent studies have already shown a relationship between skin autofluorescence and
diabetes complications, as well as the predictive value of skin autofluorescence for total and
cardiovascular mortality in type 2 diabetes. Our aim was to investigate the predictive value of
skin autofluorescence for the development of microvascular complications in type 2 diabetes.
RESEARCH DESIGN AND METHODS— At baseline, skin autofluorescence of 973
type 2 diabetic patients with well-controlled diabetes was noninvasively measured with an
autofluorescence reader. The aggregate clinical outcome was defined as the development of any
diabetes-associated microvascular complication of 881 surviving patients, which was assessed at
baseline and at the end of follow-up. Single end points were the development of diabetes-
associated retinopathy, neuropathy, and (micro)albuminuria.
RESULTS— After a mean follow-up period of 3.1 years, baseline skin autofluorescence was
significantly higher in patients who developed any microvascular complication, neuropathy, or
(micro)albuminuria but not in those who developed retinopathy. Multivariate analyses showed
skin autofluorescence as a predictor for development of any microvascular complication along
with A1C, for development of neuropathy along with smoking, and for development of (mi-
cro)albuminuria together with sex, A1C, and diabetes duration. Skin autofluorescence did not
have predictive value for the development of retinopathy, albeit diabetes duration did.
CONCLUSIONS— Our study is the first observation of skin autofluorescence measurement
as an independent predictor of development of microvascular complications in type 2 diabetes.
Diabetes Care 31:517–521, 2008
H yperglycemia, individual suscepti-bility, and lifestyle are three key fac-tors that play an important role in
the development of microvascular disease
in diabetes. One of the consequences of
hyperglycemia and the attendant in-
creased generation of free radicals is the
increased formation of advanced glyca-
tion end products (AGEs), besides the in-
creased polyol and hexosamine fluxes and
activation of protein kinase C, which all
contribute to tissue damage in diabetes
(1,2). Those AGEs can be described as the
final products of slowly occurring nonen-
zymatic glycation of proteins that form
cross-links with long-lived proteins such
as collagen (the so-called Maillard reac-
tion). They may also accumulate as a
result of oxidative stress–related glycoxi-
dation and lipoxidation pathways.
In the Diabetes Control and Compli-
cations Trial (DCCT), long-term intensive
compared with conventional treatment of
hyperglycemia in type 1 diabetic patients
improved glycemic control and delayed
the progression of microvascular compli-
cations (3). The UK Prospective Diabetes
Study and other prospective studies have
also shown an association between hyper-
glycemia and increased risk of microvas-
cular complications in type 2 diabetes (4–
6). The DCCT Skin Collagen Ancillary
Study Group showed the association of
long-term intensive treatment of hyper-
glycemia, as compared with conventional
treatment, with lower levels of AGEs in
skin collagen, and they showed that these
AGE levels in skin biopsies predicted the
risk of development or progression of mi-
crovascular disease in type 1 diabetes,
even after adjustment for A1C (7,8).
A newly described noninvasive
method to assess tissue AGEs concerns
skin autofluorescence. This method is
based on the specific fluorescence charac-
teristics of AGEs and has been validated
against specific AGE levels in skin biop-
sies in patients with diabetes or on hemo-
dialysis and in healthy control subjects
(9,10).
Recently, the relationship between
skin autofluorescence, reflecting AGE ac-
cumulation, and outcome has been stud-
ied in type 2 diabetes. Besides its relation
with chronic diabetes complications (in
cross-sectional analyses), skin autofluo-
rescence has also shown independent
predictive value for cardiovascular mor-
tality and morbidity in patients with type
2 diabetes and in patients with end-stage
renal disease undergoing hemodialysis
(10 –12) In this study, we analyzed
whether skin autofluorescence, as a
marker of AGE accumulation, can predict
the development of microvascular com-
plications in a type 2 diabetic population.
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RESEARCH DESIGN AND
METHODS— Between May 2001 and
May 2002, 973 primary care type 2 dia-
betic patients were included in the study
cohort and had a skin autofluorescence
measurement. The included patients
were all participating in a shared-care
project of the Zwolle Outpatient Diabetes
project Integrating Available Care
(ZODIAC) Study and have also been de-
scribed elsewhere (11). During follow-
up, data of 967 patients were analyzed for
this study (6 patients were lost to follow-
up). Eighty-six patients died before the
end of follow-up, and this subgroup
will be addressed separately from the sur-
viving 881 patients. Patients with a
Fitzpatrick class V–VI skin type were ex-
cluded because of the autofluorescence
reader’s limitation to measure accurately
in dark skin types (13–15). All participat-
ing patients visited the outpatient clinic at
least once a year. Follow-up ended in Jan-
uary 2005. All of the included patients
had given their informed consent, and ap-
proval by the local ethics committee had
been obtained.
Skin autofluorescence
The autofluorescence reader (prototype
of the current AGE Reader; DiagnOptics,
Groningen, the Netherlands) illuminates
a skin surface of4 cm2, guarded against
surrounding light, with an excitation light
source with peak intensity at 370 nm.
Emission light and reflected excitation
light from the skin is measured with a
spectrometer in the 300–600 nm range,
using a glass fiber. Autofluorescence was
computed by dividing the average light
intensity of the emission spectrum 420–
600 nm by the average light intensity of
the excitation spectrum 300–420 nm,
multiplied by 100 and expressed in arbi-
trary units (AU). Skin autofluorescence of
all patients was assessed at the volar side
of the arm, 10 cm below the elbow fold.
Six diabetes specialist nurses did the
autofluorescence measurements with two
identical autofluorescence reader devices.
The autofluorescence reader has been val-
idated and more extensively been de-
scribed in previous studies (9,11).
Data collection
Clinical data and laboratory results were
obtained at the time of the baseline skin
autofluorescence measurement. Serum
creatinine, nonfasting lipids (total choles-
terol, LDL cholesterol, HDL cholesterol,
and triglycerides), and urinary albumin
and creatinine were measured according
to the standard laboratory procedures.
A1C was measured with a Primus CLC-
385 using boronate affinity chromatogra-
phy and high-performance liquid
chromatography (reference value 4.0 –
6.0%). Blood pressure measurement was
a single measurement obtained after a
5-min rest with the patient in seated po-
sition, using an aneroid device. At each
visit to the outpatient clinic and at the end
of follow-up, the absence or presence of
retinopathy, neuropathy, and (micro)
albuminuria was assessed.
Clinical end points
The aggregate clinical end point was the
development of any diabetes-associated
microvascular complication, which was
defined as the presence of at least one
of the following diabetes complications
according to the American Diabetes Asso-
ciation definitions: retinopathy, neuropa-
thy, and/or (micro)albuminuria (16). The
single clinical end points were described
as the development of retinopathy,
neuropathy, or (micro)albuminuria. Ret-
inopathy was determined by an ophthal-
mologist based on retinal photography.
Presence of at least background retinopa-
thy was assumed to imply retinopathy.
Neuropathy was examined using a
5.07/10 g Semmes-Weinstein monofila-
ment, applied on the dorsum of both feet
at three different, noncallused areas (first
toe and first and fifth distal metatarsal
bone). Neuropathy was considered in
cases of diminished sensibility, which was
defined as at least two incorrect responses
after three applications at each area (two
real and one false application) (17,18).
(Micro)albuminuria at baseline was de-
fined as an albumin-to-creatinine ratio
2.5 mg/mmol for men and 3.5 mg/
mmol for women in two subsequent urine
samples or once in the year before base-
line while using an ACE inhibitor at base-
line (19). Newly developed (micro)
albuminuria at follow-up was defined as
an albumin-to-creatinine ratio 2.5 mg/
mmol for men and 3.5 mg/mmol for
women in two urine samples (one in the
year before and one at the moment during
follow-up) or an abnormal level of the al-
bumin-to-creatinine ratio in the year be-
fore the end of follow-up while using an
ACE inhibitor at follow-up.
Statistical analysis
One-way ANOVA using post hoc multi-
ple comparisons (with Bonferroni correc-
tion) was used to compare mean skin
autofluorescence between subgroups of
microvascular complications in the 881
surviving patients. Subgroups are as fol-
lows: 1) no microvascular complication at
baseline or at follow-up, 2) no microvas-
cular complication at baseline but a mi-
crovascular complication at follow-up,
and C) a microvascular complication at
baseline and at follow-up.
Univariate and multivariate multi-
nominal regression analyses were per-
formed to determine the relationship of
skin autofluorescence to the presence or
development of microvascular disease.
Patients without signs of microvascular
complications at baseline or at follow-up
formed the reference categories in these
calculations. In the multivariate analyses,
we controlled for potential confounding
risk factors for the development of micro-
vascular complications, which were de-
rived from the UKPDS findings, including
sex, diabetes duration, A1C, current
smoking, systolic blood pressure, HDL
cholesterol, LDL cholesterol, and triglyc-
erides, with the addition of BMI (4).
Odds ratios (ORs) (95% CI) for skin
autofluorescence were calculated in the
univariate and multivariate analyses. P
values 0.05 were considered statisti-
cally significant.
RESULTS— The baseline characteris-
tics of the surviving study population in-
cluding mean skin autofluorescence of
the total group are shown in Table 1.
Mean age of our study population was 66
years, 46% of whom were male, with a
relatively short median diabetes duration
of 4.0 years (interquartile range 1.5–8.1).
Eighty-five percent of this study popula-
tion with well-controlled diabetes was on
a diet and/or oral agents; the other 15% of
patients received insulin or combined in-
sulin/oral agent treatment. In the 881 sur-
vivors, the prevalence of retinopathy,
neuropathy, and (micro)albuminuria at
baseline was 19, 24, and 24%, respec-
tively, resulting in an overall percentage
of patients with diabetes-associated mi-
crovascular complication of 50%.
Table 2 shows the mean baseline skin
autofluorescence of the 881 survivors
subdivided in groups with continued ab-
sence or presence or the development of
microvascular complications at follow-
up. During a median follow-up period of
3.1 years, 61 patients (7.0%) developed
retinopathy; their baseline skin autofluo-
rescence did not differ from skin
autofluorescence levels of patients who
did not show or already had retinopathy
Autofluorescence and microvascular disease
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at baseline. However, skin autofluores-
cence was higher in the patient groups
who developed neuropathy or (mi-
cro)albuminuria compared with that in
patients without these complications. At
follow-up, newly developed neuropathy
was diagnosed in 7.5% and newly devel-
oped (micro)albuminuria in 10.1% of
patients; 12.5% of the population devel-
oped at least one microvascular complica-
tion. Skin autofluorescence at baseline
was also significantly higher in the patient
groups that developed any microvascular
complication or who already had a micro-
vascular complication at baseline com-
pared with patients who did not develop
any microvascular disease.
Multinominal logistic regression
analysis showed that skin autofluores-
cence was a strong predictor of the devel-
opment of the aggregate of microvascular
complications (OR 2.05 [95% CI 1.51–
2.80], P 0.001). Skin autofluorescence
was significantly associated with the de-
velopment of retinopathy (1.42 [1.01–
1.99], P  0.042), neuropathy (1.59
[1.15–2.19], P  0.005), and (mi-
cro)albuminuria (1.73 [1.28–2.34], P 
0.001). After correction for the confound-
ing risk factors, baseline skin autofluores-
cence still appeared to be significantly
associated with the development of these
end points, except for retinopathy (1.21
[0.83–1.74], P  0.32) (Table 3). Diabe-
tes duration at baseline was the only sig-
nificant independent variable for
development of retinopathy in this multi-
variate analysis (1.10 [1.06–1.15], P 
0.001). Surviving smokers less often de-
veloped neuropathy compared with non-
smokers. In the nonsurviving group (86
patients), 70% had a microvascular com-
plication at baseline; there were 23 non-
surviving smokers. Seventy percent of the
nonsurviving smokers already had a mi-
crovascular complication at baseline, and
13% of the nonsurviving smokers devel-
oped a microvascular complication before
they died.
When baseline skin autofluorescence
levels are categorized in subgroups of
practically feasible levels of skin autofluo-
rescence (three categories in rounded ter-
tiles: skin autofluorescence 2.35 AU,
2.35 skin autofluorescence3.00 AU,
and skin autofluorescence 3.00 AU);
those in the category skin autofluores-
cence3.00 AU do have a higher chance
to develop a microvascular complication
compared with patients with a lower skin
autofluorescence level (Table 4).
Table 1—Characteristics of the type 2 diabetic patients
Characteristic
n 881
Age (years) 66  11
Sex (male/female) 406/475
Smoking (%) 19
BMI (kg/m²) 29.4  4.8
Systolic blood pressure (mmHg) 146  20
Diabetes duration (years) 4.0 (1.5–8.1)
A1C (%) 6.6 (6.0–7.6)
Creatinine (mol/l) 95  19
Creatinine clearance (ml/min) 77  27
Urinary albumin-to-creatinine ratio 1.41 (0.76–3.79)
Total cholesterol (mmol/l) 5.2  1.0
HDL cholesterol (mmol/l) 1.3  0.3
LDL cholesterol (mmol/l) 2.9  0.9
Triglycerides in mmol/l 2.1 (1.4–2.9)




Macrovascular disease (%) 37
Skin autofluorescence (total group) (AU) 2.74  0.7
Values are means  SD or median (interquartile range) unless otherwise indicated. Reference values of the
laboratory: A1C 4.0–6.0%, creatinine 70–110 mol/l, creatinine clearance (Cockcroft-Gault formula) 80–
120 ml/min, urinary albumin-to-creatinine ratio 0–2.5, total cholesterol 3.5–5.0 mmol/l, HDL cholesterol
0.9–1.7 mmol/l, LDL cholesterol 3.6–4.4 mmol/l, and triglycerides 0.6–2.2 mmol/l.






present B vs. A C vs. A C vs. B
Microvascular complication
Retinopathy 2.69  0.73 2.88  0.74 2.91 0.72 0.20 0.22 0.02
n 647 61 169 (0.04 to 0.43) (0.07–0.37) (0.24 to 0.29)
P 0.14 0.002 1.00
Neuropathy 2.67 0.72 2.93 0.75 2.88 0.75 0.26 0.21 0.05
n 596 66 215 (0.03–0.49) (0.07–0.35) (0.29 to 0.20)
P 0.019 0.001 1.00
(Micro)albuminuria 2.62 0.68 2.91 0.67 2.97 0.83 0.28 0.34 0.06
n 570 87 207 (0.09–0.48) (0.20–0.48) (0.16 to 0.28)
P 0.002 0.001 1.00
Any 2.52 0.69 2.86 0.66 2.88 0.75 0.34 0.36 0.01
n 322 109 441 (0.15–0.53) (0.23–0.48) (0.17 to 0.20)
P 0.001 0.001 1.00
Data are means  SD of skin autofluorescence in AUs within the group or mean differences between groups (95% CI) (ANOVA with Bonferroni correction). t0,
baseline; tfu, follow-up.
Gerrits and Associates
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CONCLUSIONS— Our study pro-
vides the first evidence that skin autofluo-
rescence is an independent predictor of
development of microvascular complica-
tions in a population of patients with
well-controlled type 2 diabetes. Sepa-
rately, this also holds for the development
of neuropathy and (micro)albuminuria
(and in univariate analysis for retinopa-
thy). This noninvasive marker of tissue
AGE accumulation may reflect the delete-
rious effects of long-term glycemic and
oxidative stress. Meerwaldt et al. (12) re-
cently showed that skin autofluorescence
is a predictor of 5-year coronary heart dis-
ease and mortality in diabetes. The
present study shows that skin autofluo-
rescence also has a predictive value for the
development of microvascular complica-
tions that, in the analysis of this study, is
superior to that of many other commonly
used risk predictors, such as diabetes du-
ration and A1C, in type 2 diabetes. This
conclusion is applicable for primary care
type 2 diabetic patients treated according
to current standards, which is the large
majority of type 2 diabetes patients in the
Netherlands.
The DCCT/EDIC (Epidemiology of
Diabetes Interventions and Complica-
tions) substudy already showed the pre-
dictive value for skin AGE levels obtained
from skin biopsies for the progression of
microvascular complications in patients
with type 1 diabetes (8). Our study pop-
ulation consisted of type 2 diabetic pa-
tients with skin AGE level assessment by
means of a noninvasive, rapid method.
Another difference is that the DCCT/
EDIC substudy investigated the develop-
ment as well as the progression of
microvascular complications. The limited
follow-up period; the low rate of clearly
classifiable progression of the micro-
vascular complications, especially reti-
nopathy; and the confounding role of
introduced medication made us decide to
restrict our study to the evaluation of the
development of microvascular complica-
tions and not to address progression of
these diabetes complications.
In retinopathy, skin autofluorescence
turned out to have no prognostic value in
the multivariate analysis. Possible expla-
nations are the short follow-up period
and the smaller amount of patients who
developed retinopathy versus the other
complications. Moreover, the different
pathophysiologic mechanisms of micro-
vascular damage in the different organs
(retina, kidneys, and neurons) could play
a role in the differences in incidence rates
of outcomes. In particular, the pathobiol-
ogy of retinopathy might be different
from that of the kidney and neurologic
system as a result of a different role of
vascular endothelial growth factor as a
possible mediator for proliferation (20).
(Micro)albuminuria is an early clini-
cal sign of diabetic nephropathy; when
left untreated, it predicts a high risk for
the development of progressive renal
damage, which eventually may lead to
end-stage renal disease. Progressive renal
disease is also associated with a vastly in-
creased cardiovascular risk. This study
defined (micro)albuminuria as a sign of
microvascular complications with the in-
tention to reflect early stages of diabetic
nephropathy.
In the predictive analyses, the non-
surviving patients were excluded from the
analyses. These nonsurvivors had mark-
edly increased skin autofluorescence val-
ues, but they also had a very high
prevalence of microvascular complica-
tions at baseline (70%), so this does not
reduce the strength of the relation be-
tween skin autofluorescence and micro-
vascular complications.
Ethnicity is one of the mentioned UK-
PDS confounding risk factors for the de-
velopment of microvascular disease.
Because of the limitation of measuring
skin autofluorescence in dark skin types
associated with the prototype of the AGE
Table 3—Variables related to the development of microvascular complications in type 2 diabetes by multinominal logistic regression analysis
Variables
Any microvascular
complication Retinopathy Neuropathy (Micro)albuminuria
P OR (95% CI) P OR (95% CI P OR (95% CI) P OR (95% CI)
Skin AF 0.001 2.02 (1.45–2.81) 0.32 1.21 (0.83–1.74) 0.026 1.50 (1.05–2.14) 0.001 1.88 (1.36–2.61)
Sex 0.02 0.55 (0.33–0.90) 0.91 0.97 (0.53–1.75) 0.78 1.09 (0.61–1.93) 0.001 0.42 (0.25–0.71)
A1C 0.004 1.30 (1.09–1.55) 0.13 1.18 (0.95–1.45) 0.87 1.02 (0.82–1.26) 0.034 1.21 (1.01–1.44)
Diabetes duration 0.66 1.01 (0.96–1.06) 0.001 1.10 (1.06–1.15) 0.032 1.04 (1.00–1.08) 0.04 0.95 (0.90–0.997)
Smoking 0.07 0.56 (0.29–1.05) 0.09 0.48 (0.21–1.11) 0.011 0.29 (0.11–0.75) 0.96 1.02 (0.56–1.85)
Systolic blood pressure 0.43 1.01 (0.99–1.02) 0.39 1.01 (0.99–1.02) 0.49 1.01 (0.99–1.02) 0.18 1.01 (0.996–1.02)
LDL cholesterol 0.48 1.09 (0.85–1.40) 0.66 0.93 (0.69–1.27) 0.35 0.87 (0.64–1.17) 0.30 1.15 (0.89–1.49)
HDL cholesterol 0.26 0.62 (0.27–1.43) 0.36 0.63 (0.23–1.70) 0.081 0.41 (0.15–1.12) 0.40 0.38 (0.15–0.96)
Triglycerides 0.54 0.94 (0.78–1.14) 0.41 0.91 (0.72–1.15) 0.85 0.98 (0.79–1.22) 0.19 0.87 (0.71–1.07)
BMI 0.27 1.03 (0.98–1.08) 0.33 1.03 (0.97–1.09) 0.56 0.98 (0.93–1.04) 0.39 1.02 (0.97–1.08)
AF, autofluorescence measured with the autofluorescence reader (see RESEARCH DESIGN AND METHODS).
Table 4—Prediction of newly developed microvascular complications subdivided into three skin autofluorescence (AF) groups
Microvascular complication n* Skin AF 2.35 AU 2.35  Skin AF 3.00 AU Skin AF 3.00 AU
Retinopathy 708 15/241 (6.2) 18/251 (7.2) 28/216 (13.0)
Neuropathy 662 11/219 (5.0) 27/247 (10.9) 28/196 (14.3)
(Micro)albuminuria 657 18/225 (8.0) 31/253 (12.3) 38/179 (21.2)
Any 431 23/161 (14.3) 41/167 (24.6) 45/103 (43.7)
Data are n (%) of newly developed microvascular complications of subgroups compared with the group who did not develop a microvascular complication. *Patients
who did not have a complication at baseline. Subgroups of skin AF are tertiles rounded to a practical level.
Autofluorescence and microvascular disease
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reader used in the present study, individ-
uals with dark skin had to be excluded.
Over 95% of the participants were Cau-
casian; therefore, ethnicity was not taken
into account in the analyses. Further de-
velopments of the AGE reader may hope-
fully enable measurements in dark skin
type in future investigations.
Lutgers et al. (11) previously described
the other limitations of the autofluores-
cence reader as a marker of tissue AGE
accumulation: nonfluorescent AGEs will
not be measured with the autofluorescence
reader, and other tissue components that
fluoresce in the same range of wavelength
might be confounders.
In conclusion, our study confirms
skin autofluorescence as a helpful clinical
method to identify type 2 diabetic pa-
tients at risk for developing any microvas-
cular complication, neuropathy, and
(micro)albuminuria. Further investiga-
tion with longer follow-up needs to be
done to assess whether skin autofluores-
cence is a factor in the development of
diabetic retinopathy and to assess the re-
lationship of skin autofluorescence and
the progression of microvascular compli-
cations. Its noninvasive and time-saving
application makes the autofluorescence
reader an easy clinical tool that is useful in
the outpatient clinic in risk assessment
and for monitoring changes in accumula-
tion of tissue AGEs reflecting long-term
glycemic stress.
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